"We will be manufacturing products like deltiazem, pentoxyfiline, ciprofloxacin, rexofenadine, iopamidol and naproxen at our Vizag unit, which will help us in maintaining our profit margins of around 11 per cent," Anu's Labs' Managing Director, K Hari Babu, told reporters here today.
The company's existing manufacturing facility at Shadnagar near Hyderabad has a 2,000 tonnes per annum capacity to manufacture drug intermediates.
It has an over 60 per cent domestic market share of Dichloro Fluoro Acetophenone (DCFA), a key intermediate used in the manufacture of Ciprofloxacin. It is also one of the largest manufacturers globally of DCFA.
The company's clientele includes Dr Reddy's Laboratories, Matrix Laboratories, Aurobindo Pharma, Neuland Laboratories and Divi's Laboratories.
The company's state-of-the-art R&D facilities, located at Balanagar, Hyderabad, support the process of product development, contract research and customised synthesis programmes of the organisation.